Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma
Peter Martin(Northwestern University), Kristie A. Blum(Emory University), Joseph M. Flynn(The Ohio State University), Kami J. Maddocks(The Ohio State University), John P. Leonard(New York University), Leslie A. Andritsos(University of New Mexico), Jia Ruan(Cornell University), Katherine Noto(Cornell University), Jeffrey A. Jones(The Ohio State University), Beth Christian(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Selina Chen‐Kiang(NewYork–Presbyterian Hospital), Maurizio Di Liberto(Howard Hughes Medical Institute), Richard R. Furman(Cornell University)
Cited by 11
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k